SPG20; spastic paraplegia 20 (Troyer syndrome); KIAA0610; SPARTIN; TAHCCP1; OTTHUMP00000018254; spastic paraplegia 20; spastic paraplegia 20, spartin (Troyer syndrome); trans-activated by hepatitis C virus core protein 1; SPG20 antibody; spastic paraplegia 20 (Troyer syndrome) antibody; KIAA0610 antibody; SPARTIN antibody; TAHCCP1 antibody; OTTHUMP00000018254 antibody; spastic paraplegia 20 antibody; spastic paraplegia 20; spartin (Troyer syndrome) antibody; trans-activated by hepatitis C virus core protein 1 antibody; SPARTIN

For Research Use Only. Not for use in diagnostic procedures.

Polyclonal

Goat

Purified from goat serum by ammonium sulphate precipitation followed by antigen affinity chromatography using the immunizing peptide.

Supplied at 0.5 mg/ml in Tris saline, 0. 02% sodium azide, pH7.3 with 0.5% bovine serum albumin.

100ug specific antibody in 200ul (lot specific)

Aliquot and store at -20 degree C. Minimize freezing and thawing.

Manufactured in an ISO 9001:2008 Certified Laboratory.

Small volumes of anti-SPG20 antibody vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Peptide ELISA (EIA), Western Blot (WB), Immunofluorescence (IF)

Peptide ELISA: Antibody detection limit dilution 1: 8000.
Western Blot: Approx 70kDa band observed in lysates of cell line HeLa (calculated MW of 72.8kDa according to NP_055902.1). Recommended concentration: 1-3ug/ml.
Immunofluorescence: HeLa show dimished signals after knock down of expresssion by introduction of siRNA.

(2ug/ml) staining of HeLa lysate (35ug protein in RIPA buffer). Primary incubation was 1 hour. Detected by chemiluminescence.

(2ug/ml) staining of methanol-fixed HeLa before (left) and after (right) introduction of siRNA.

72,833 Da

spastic paraplegia 20 (Troyer syndrome)

spartin

Spartin

KIAA0610; TAHCCP1??[Similar Products]

SPG20_HUMAN

This gene encodes a protein containing a MIT (Microtubule Interacting and Trafficking molecule) domain, and is implicated in regulating endosomal trafficking and mitochondria function. The protein localizes to mitochondria and partially co-localizes with microtubules. Stimulation with epidermal growth factor (EGF) results in protein translocation to the plasma membrane, and the protein functions in the degradation and intracellular trafficking of EGF receptor. Multiple alternatively spliced variants, encoding the same protein, have been identified. Mutations associated with this gene cause autosomal recessive spastic paraplegia 20 (Troyer syndrome). [provided by RefSeq, Nov 2008]

SPG20: May be implicated in endosomal trafficking, or microtubule dynamics, or both. Defects in SPG20 are the cause of spastic paraplegia autosomal recessive type 20 (SPG20); also known as Troyer syndrome (TRS). Spastic paraplegia is a neurodegenerative disorder characterized by a slow, gradual, progressive weakness and spasticity of the lower limbs. Rate of progression and the severity of symptoms are quite variable. Initial symptoms may include difficulty with balance, weakness and stiffness in the legs, muscle spasms, and dragging the toes when walking. In some forms of the disorder, bladder symptoms (such as incontinence) may appear, or the weakness and stiffness may spread to other parts of the body. SPG20 is characterized by dysarthria, distal amyotrophy, mild developmental delay and short stature.

Protein type: Unknown function

Chromosomal Location of Human Ortholog: 13q13.3

Cellular Component: cytoplasm; lipid particle; midbody; mitochondrial outer membrane; plasma membrane; synapse

Molecular Function: protein binding; ubiquitin protein ligase binding

Biological Process: abscission; cell division; negative regulation of BMP signaling pathway; negative regulation of collateral sprouting in the absence of injury; neuromuscular process; regulation of mitochondrial membrane potential

Disease: Spastic Paraplegia 20, Autosomal Recessive

All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.

While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.